Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.75 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.75 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.75 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.75 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.75 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.75 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480443 | 1.00 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477806 | 0.91 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5477805 | 0.91 | LRRK2 (0.83) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3749415 | 0.89 | LRRK2 (0.74) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL249340 | 0.89 | LRRK2 (0.59) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL249341 | 0.89 | LRRK2 (0.59) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18505869 | 0.86 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14674660 | 0.86 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3804991 | 0.86 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5474728 | 0.86 | LRRK2 (0.75) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | LRRK2 1753/4885PSEN1 1618/4885PSEN2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.